Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 20/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.66 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.66 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650500 | 0.88 | F2 (1.00) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5649276 | 0.85 | F2 (1.00) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5649666 | 0.85 | F2 (1.00) | F2 | |
| SCHEMBL5647349 | 0.85 | F2 (0.73) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5647354 | 0.85 | F2 (0.73) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5650714 | 0.82 | F2 (1.00) | F2 | |
| SCHEMBL5648900 | 0.82 | F2 (1.00) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5645792 | 0.81 | F2 (1.00) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5647449 | 0.81 | F2 (0.98) | F2 | |
| SCHEMBL5648082 | 0.80 | F2 (0.66) | F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| EP-1713774-A1 | NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075424-A1 | NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | PLG, F2, PLAT | F2 2/4885PRSS1 20/4885PRSS2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.